Attention deficit

MindAmp - Mindfulness Headphones for Meditation & Mental Wellness Announces Launch

Retrieved on: 
Tuesday, October 12, 2021
EEG, Mindfulness, Brain, Insomnia, Electronic oscillator, Relaxation, Self-control, GLOBE, Sleep, Depression, Hospital, Meditation, CEO, Anxiety, Attention deficit, Medical imaging

HONG KONG, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Today, MindAmp announced the launch of a revolutionary system for meditation and mental wellness.

Key Points: 
  • HONG KONG, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Today, MindAmp announced the launch of a revolutionary system for meditation and mental wellness.
  • Utilizing brain-sensing technology, MindAmp headphones help users quickly achieve a meditative state that helps to refocus, relieve anxiety, reduce stress, and improve sleep quality.
  • MindAmp is available now: https://www.kickstarter.com/projects/mindamp/mindamp-a-mindfulness-headp...
    MindAmp are in-ear headphones created for mindfulness with advanced sensors that guide users quickly and easily into meditation.
  • MindAmp - Mindfulness Headphones for meditation & mental wellness gives people a faster, more effective way to achieve mindful meditation for relaxation, stress relief, and sharper mental focus.

Paw for Good launches crowdfunding program to create a mutually beneficial ecosystem by transforming stray dogs into instructors for people with special needs

Retrieved on: 
Friday, September 10, 2021

The program aims to support Paw for Good to help more people in need to benefit from interacting with educational support dogs.

Key Points: 
  • The program aims to support Paw for Good to help more people in need to benefit from interacting with educational support dogs.
  • To break the stereotype that service dogs are limited to specific breeds, the team purposely chose stray dogs and train them to become educational support dogs .
  • The educational support dogs can support people with autism spectrum disorder (ASD), attention deficit and hyperactivity disorder (ADHD), depressive disorder and other disabilities.
  • Qualified educational support dogs can assist people with ASD, ADHD, depressive disorders or disabilities as well aschildren with special needs.

Corium Launches Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Stimulants, Methylphenidate, Amphetamine, Nootropics, Norepinephrine-dopamine reuptake inhibitors, Attention deficit hyperactivity disorder, Pemoline, Dexmethylphenidate, Attention deficit, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

Corium, a wholly-owned portfolio company of Gurnet Point Capital (GPC), will lead the U.S. commercialization of AZSTARYS.

Key Points: 
  • Corium, a wholly-owned portfolio company of Gurnet Point Capital (GPC), will lead the U.S. commercialization of AZSTARYS.
  • Corium will offer programs to support patients, providers, and health systems through CoriumCaresTM.
  • AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.
  • Do not take AZSTARYS if you or your child are:
    allergic to serdexmethylphenidate, methylphenidate, or any of the ingredients in AZSTARYS.

2021 Worldwide Attention Deficit Hyperactivity Disorder Industry - Understand Targeted Population for Research and Development - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Health, General Health, Psychiatric diagnosis, Psychiatry, Medicine, Articles, Childhood psychiatric disorders, Attention deficit hyperactivity disorder, Amphetamine, Educational psychology, Attention deficit, Disease, Attention deficit hyperactivity disorder controversies, Bipolar disorder

b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Attention Deficit Hyperactivity Disorder patients, history of the disease at the population level (Attention Deficit Hyperactivity Disorder prevalence, Attention Deficit Hyperactivity Disorder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nAttention Deficit Hyperactivity Disorder patient flow: Attention Deficit Hyperactivity Disorder prevalence, diagnosed, and drug-treated patients\nDemographics: Attention Deficit Hyperactivity Disorder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Attention Deficit Hyperactivity Disorder market sizing, assessing market potential, and developing drug forecast models\nIdentify Attention Deficit Hyperactivity Disorder patients segments through age groups, gender, and disease sub-types\nEvaluate Attention Deficit Hyperactivity Disorder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005615/en/\n'

NLS Pharmaceutics Ltd. Announces Notice of Allowance of a New Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy

Retrieved on: 
Thursday, January 21, 2021
Intellectual property law, Psychoactive drugs, Canadian patent law, Canadian intellectual property law, Childhood psychiatric disorders, Psychiatric diagnosis, Canadian Intellectual Property Office, Canadian trademark law, Attention deficit hyperactivity disorder, CIPO, Attention deficit, Mazindol

On November 23, 2020, the Canadian Intellectual Property Office (CIPO) issued a similar notice of allowance for the counterpart Canadian application.

Key Points: 
  • On November 23, 2020, the Canadian Intellectual Property Office (CIPO) issued a similar notice of allowance for the counterpart Canadian application.
  • NLS awaits the impending grant of the European and Canadian patents.
  • 17724102, entitled "A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)", has been examined and allowed for issuance as a patent by the EPO on January 21, 2021.
  • This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws.

Europe Attention Deficit Hyperactivity Disorder Market and Competitive Landscape 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 23, 2020
Health, Pharmaceutical, Psychiatry, Abnormal psychology, Attention deficit hyperactivity disorder, Educational psychology, Psychiatric diagnosis, Childhood psychiatric disorders, Attention deficit, Déficit, Hyperkinesis, Book:Pharmacy drugs pt 1

The "Europe Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2020, provides comprehensive insights into the Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Attention Deficit Hyperactivity Disorder market size and drug sales.
  • Attention Deficit Hyperactivity Disorder pipeline: Find out drugs in clinical trials for the treatment of Attention Deficit Hyperactivity Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Attention Deficit Hyperactivity Disorder epidemiology: Find out the number of patients diagnosed (prevalence) with Attention Deficit Hyperactivity Disorder by countries
    Attention Deficit Hyperactivity Disorder drugs: Identify key drugs marketed and prescribed for Attention Deficit Hyperactivity Disorder in the US, including trade name, molecule name, and company
    Attention Deficit Hyperactivity Disorder drugs sales: Find out the sales value for Attention Deficit Hyperactivity Disorder drugs by countries
    Attention Deficit Hyperactivity Disorder market valuations: Find out the market size for Attention Deficit Hyperactivity Disorder drugs in 2019 by countries.

KemPharm to Present at Upcoming September Investor Conferences

Retrieved on: 
Wednesday, September 2, 2020
Psychoactive drugs, Euphoriants, Morphinans, Amphetamine, Stimulants, Benzhydrocodone, Attention deficit hyperactivity disorder, Hydrocodone, Pemoline, Attention deficit, Drug

KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.

Key Points: 
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .
  • KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Worldwide Attention Deficit Hyperactivity Disorder Industry (2020 to 2024) - Identify Key Drugs Marketed and Prescribed

Retrieved on: 
Thursday, June 18, 2020
Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Abnormal psychology, Educational psychology, Psychiatric diagnosis, Methylphenidate, Attention deficit, Déficit, Hyperkinetic disorder, Adult attention deficit hyperactivity disorder

This report provides comprehensive insights into the Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Attention Deficit Hyperactivity Disorder market size and drug sales.
  • This research covers the following:
    Attention Deficit Hyperactivity Disorder treatment options, Attention Deficit Hyperactivity Disorder late stage clinical trials pipeline, Attention Deficit Hyperactivity Disorder prevalence by countries, Attention Deficit Hyperactivity Disorder market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Attention Deficit Hyperactivity Disorder pipeline: Find out drugs in clinical trials for the treatment of Attention Deficit Hyperactivity Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Attention Deficit Hyperactivity Disorder epidemiology: Find out the number of patients diagnosed (prevalence) with Attention Deficit Hyperactivity Disorder by countries
    Attention Deficit Hyperactivity Disorder drugs: Identify key drugs marketed and prescribed for Attention Deficit Hyperactivity Disorder in the US, including trade name, molecule name, and company
    Attention Deficit Hyperactivity Disorder drugs sales: Find out the sales value for Attention Deficit Hyperactivity Disorder drugs by countries
    Attention Deficit Hyperactivity Disorder market valuations: Find out the market size for Attention Deficit Hyperactivity Disorder drugs in 2019 by countries.

Akili Announces FDA Clearance of EndeavorRxTM for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game

Retrieved on: 
Monday, June 15, 2020
Entertainment, Mobile Entertainment, Pharmaceutical, Family, Consumer, Mental health, Children, Clinical trials, Biotechnology, FDA, Electronic Games, Health, Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Psychiatric diagnosis, Educational psychology, Abnormal psychology, Methylphenidate, Attention deficit, EndeavorRx, Akili

Akili today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for EndeavorRxTM (AKL-T01) as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).

Key Points: 
  • Akili today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for EndeavorRxTM (AKL-T01) as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).
  • Were proud to make history today with FDAs decision," said Eddie Martucci, Ph.D., chief executive officer of Akili.
  • Akilis flagship product, EndeavorRx, is a prescription digital treatment to address inattention in children with attention deficit hyperactivity disorder (ADHD).
  • EndeavorRxTM and Akili CareTM are trademarks or registered trademarks of Akili Interactive Labs, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005739/en/

Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape to 2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 15, 2020
Health, Pharmaceutical, Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Psychiatric diagnosis, Cognition, Educational psychology, Methylphenidate, Attention deficit, Déficit, Hyperkinetic disorder, Sluggish cognitive tempo

The "Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following:
    Attention Deficit Hyperactivity Disorder treatment options, Attention Deficit Hyperactivity Disorder late stage clinical trials pipeline, Attention Deficit Hyperactivity Disorder prevalence by countries, Attention Deficit Hyperactivity Disorder market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Attention Deficit Hyperactivity Disorder pipeline: Find out drugs in clinical trials for the treatment of Attention Deficit Hyperactivity Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Attention Deficit Hyperactivity Disorder epidemiology: Find out the number of patients diagnosed (prevalence) with Attention Deficit Hyperactivity Disorder by countries
    Attention Deficit Hyperactivity Disorder drugs: Identify key drugs marketed and prescribed for Attention Deficit Hyperactivity Disorder in the US, including trade name, molecule name, and company
    Attention Deficit Hyperactivity Disorder drugs sales: Find out the sales value for Attention Deficit Hyperactivity Disorder drugs by countries
    Attention Deficit Hyperactivity Disorder market valuations: Find out the market size for Attention Deficit Hyperactivity Disorder drugs in 2019 by countries.